SCM
PRLD icon

Sterling Capital Management’s Prelude Therapeutics PRLD Stock Holding History

Sterling Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-227
Closed -$174 – 3361
2025
Q1 		$174 Buy
227
+185
+440% +$173 ﹤0.01% 3100
2024
Q4 		$54 Hold
42
– – ﹤0.01% 3209
2024
Q3 		$87 Buy
+42
New +$195 ﹤0.01% 3203

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Sterling Capital Management's PRLD Position: Q2 2025 in Review

Sterling Capital Management sold out of Prelude Therapeutics (PRLD) in Q2 2025, closing a stake of 227 shares — an estimated $174 sold.

Sterling Capital Management first reported a position in PRLD in Q3 2024 and held it in 3 quarters. The position peaked at $174 in Q1 2025. 50 funds tracked by Wall St. Rank hold PRLD as of Q2 2025.

  • Sterling Capital Management reported no remaining Prelude Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sterling Capital Management sold 227 Prelude Therapeutics shares in Q2 2025, an estimated $174.
  • Sterling Capital Management first reported a position in Prelude Therapeutics in Q3 2024 and held it in 3 quarters.
  • Sterling Capital Management's Prelude Therapeutics position peaked at $174 in Q1 2025.
  • 50 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.